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 “But in the end, it’s only a passing thing...this shadow.  
Even darkness must pass.” 






POPULAR SCIENCE SUMMARY OF THE THESIS 
Individual cells within multicellular organisms must communicate with each other in order to 
ensure the proper function of the organism as a whole. Cell communication can be of many 
forms and one of which is by direct contact between interacting cells. Much like using the sense 
of touch as a form of language, cells use proteins on their surface to sense other interacting 
cells. It has been hypothesized that cells communicate with each other through their cell surface 
proteins and react differently depending on the distances and patterns these proteins are placed 
on. These distances are at the nanoscale and it is very difficult to build protein patterns at such 
a small scale and with precision. A way to achieve this is to use DNA molecules to build 
structures that allow attaching of proteins at the nanoscale. In this thesis, we use this method to 




Juxtracrine signaling between apposing membrane receptors and ligands is an important class 
of intercellular communication. Much focus has been directed towards studying the 
biochemical interactions between receptors and ligands, their surface expression levels and 
signaling activities for driving downstream signaling processes. However, the lateral 
distribution of receptors/ligands on the membrane has been gaining increasing significance in 
modulating intercellular signaling. Nevertheless, little is known about the cellular mechanisms 
of interpreting this biophysical factor during ligand/receptor signaling. The work in thesis is 
based on the hypothesis that cells use information from the spatial organization of their surface 
ligands/receptors to direct intracellular signaling. To address this, we have employed the power 
of DNA origami technology to manipulate ligand spatial distances with nanometer precision 
and constrain their cognate receptors into defined configurations in ephrin/Eph signaling and 
the T-cell negative regulators PD-L1/PD-1 on T cell signaling. With this approach, we 
demonstrated that modulating the nanoscale organization of ephrin-A5 ligands contributed to 
divergent transcriptional profiles in human glioblastoma cells (paper I). We also showed that 
the nanoscale organization of PD-L1 regulates T-cell activation and sizes of PD-1 clusters 
(paper II). In summary, this work describes that the spatial organization of ligands/receptors at 
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1 LITERATURE REVIEW 
1.1 SPATIAL ORGANIZATION OF CELL MEMBRANE PROTEINS  
Cell communication is mediated by several cues that are broadly categorized as autocrine, 
paracrine, endocrine and juxtacrine signals. Juxtacrine cell signaling is based on direct contact 
of interacting cells. The recognition and binding of cell surface receptors to their cognate 
ligands on juxtaposed cells is translated into intracellular signals that mediate cell behavior (e.g 
change in gene expression). An intrinsic feature of juxtacrine signaling is the assembly of cell 
surface proteins into multimolecular complexes on the membrane. In particular, the physical 
location of membrane proteins and their organization at cell-cell junctions have emerged as a 
pivotal mediator in signal transduction1–3. The coordinated assembly of membrane-associated 
proteins into organized patterns is crucial for localization, enrichment, amplification or 
depletion of downstream signals over the course of cell signaling1. Erythropoietin-producing 
hepatoma (Eph) signaling and the T-cell immunological synapse are examples that exemplify 
the integral role of spatial organization within cellular interfaces for modulating signal 
transduction. 
1.2 EPHS AND EPHRINS 
Receptor tyrosine kinases (RTK) are a major type of enzyme-linked membrane receptors which 
regulate core cellular and developmental processes such as cell proliferation, differentiation 
and migration4. Eph receptors are the largest subfamily of RTK, consisting of nine EphA 
(EphA1 – A8 and A10) and four EphB receptor classes (EphB1 – B4 and B6) in humans5. 
Ephrins and Ephs have widespread roles in developmental and physiological processes 
including axon guidance, tissue patterning and segregation, angiogenesis, cell migration, 
adhesion and repulsion6. The EphA1 receptor was first cloned in human hepatocellular 
carcinoma in 1987 and then later identified as an oncogene7,8. In contrast to other RTK ligands 
which are generally soluble, Eph signaling is typically activated by Eph receptor-interacting 
(ephrin) proteins tethered to the cell membrane by a glycosylphosphatidylinositol (GPI) anchor 
(type A) or a transmembrane domain (type B) in a juxtacrine manner5. While EphA and EphB 
receptors generally bind to ephrins-A and B respectively, cross-interactions between classes of 
EphA and ephrin-B, or EphB and ephrin-A have been identified9,10. Unlike classical RTK 
signaling, Ephs and ephrins have dual receptor and ligand roles which can elicit bidirectional 
signaling in cells interacting in trans6. This phenomenon is described by signaling cascades 
that occur in the Eph-expressing cell (“forward signaling”) and the ephrin-expressing cell 
(“reverse signaling”). Forward signaling mainly involves Eph kinase-dependent activity while 
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reverse signaling is based on ephrin recruitment of Src family kinases11. Further, the 
complexity of ephrin-Eph signaling is demonstrated by evidence of Ephs and ephrins 
interacting in cis on the same cell surface leading to inhibition of Eph forward signaling12–14. 
Moreover,  ligand and kinase-independent signaling have been discovered for certain Eph 
receptors15–17, exemplifying the versatility of Eph signaling. However, this thesis focuses on 
Eph forward signaling. 
1.2.1 Mechanistic concepts of Eph activation 
Formation of higher-order ephrin/Eph clusters on the cell membrane is essential for robust Eph 
signal propagation18. Early in vitro studies found that potent Eph activation was induced by 
ephrin ligands expressed on the cell membrane and soluble oligomers from antibody pre-
clustering of ephrins fused to antibody Fc fragment18–20. For certain Eph receptors like EphA2, 
the soluble ephrin-Fc dimers are able to cause receptor clustering and activation21,22. However, 
while Eph activation (typically indicated by receptor tyrosine phosphorylation) is induced by 
ephrin dimers and tetramers/oligomers, it is the tetramers/oligomers that result in functional 
cellular responses18. On the contrary, soluble ephrin monomers act as antagonists by binding 
to Eph receptors but do not elicit receptor tyrosine phosphorylation19. Contradictory findings 
have reported EphA2 receptor activation by soluble ephrin-A1 monomers that were released 
through membrane proteolytic cleavage from cancer cells, through unclear mechanisms23,24.  
Early crystallography studies of ephrin/Eph complexes have revealed hetero-tetramers formed 
by EphB2 and ephrin-B2 homodimers25, as well as hetero-dimers of EphB2–ephrinA5 and 
EphB4–ephrin-B29,26. Similar structures were later identified for EphA2 and ephrin-A1/A5 
complexes27–29. These data contributed to the working ligand- and kinase-dependent Eph 
signaling model of which formations of ephrin-Eph hetero-dimers and hetero-tetramers lead to 
subsequent lateral assembly of higher-order clusters that can contain unliganded receptors6,20,29 
(Figure 1). The exact mechanisms underlying the stages of dimerization and tetramerization 
are still poorly understood. Nevertheless, there is a general consensus that tetramerization is 
the minimal unit for signal amplification leading up to functional cellular outcomes18. 
Interestingly, intra-class Eph receptors show unique clustering behaviors as evidenced by 
oligomeric versus array-like configurations in EphA4 and EphA2 clusters respectively30. In 
addition, EphA2 receptors can assemble into unliganded dimers in transfected human 
embryonic kidney (HEK293T) cells31. Signal termination is mediated by the trans-endocytosis 
of the large clusters in either ephrin or Eph-expressing cell32. This process involves proteolytic 
cleavage of Eph or ephrins by metalloproteases and g-secretases at the cell membrane. In 
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particular, a disintegrin and metalloprotease domain-containing protein 10 (ADAM10) 
associates with EphA receptors and cleaves the ephrins interacting in trans. This results in 
membrane internalization of the complex containing the receptor and the ligand extracellular 
domains33.  
Figure 1. The proposed working model of Eph receptor activation. A single ephrin ligand 
binding to a Eph receptor triggers receptor conformation change and dimerization. Two Eph-
ephrin dimers form a tetramer which induces strong receptor phosphorylation (blue circles). 
The tetramers can further form larger assemblies by recruiting ligand-bound and unliganded 
Eph receptors.  
There has been compelling evidence demonstrating the importance of size, composition and 
spatial organization of ephrin-Eph clusters in Eph signaling strength and overall cellular 
responses. Experiments using synthetic dimerizers found EphB2 oligomers with higher 
receptor autophosphorylation levels than dimers and EphB-related cytoskeleton collapse 
responses from small clusters34. These responses were found correlated to the composition of 
oligomers versus dimers within signaling clusters34. Restriction of lateral transport and 
assembly of EphA2 clusters by physical patterns on supported lipid bilayers led to reduced 
recruitment of effector proteins, altered actin cytoskeleton and inhibition of ephrin trans-
endocytosis35,36. Similarly, spatial modulation of EphB4 signaling using these patterned 
substrates disrupted cluster formation and inhibited neural stem cell differentiation37. Also, 
stimulation of neural stem cells with multivalent ephrin-B2 conjugates potently enhanced 
transcriptional activation of neuronal differentiation38. Furthermore, DNA origami 
nanofabrication of varying ephrin-A5 nanoscale patterns modulated EphA2 phosphorylation 
levels and invasiveness of human breast cancer cells39. Overall, these studies strongly suggest 
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that ephrin/Eph receptor signaling is regulated by its ability to spatially cluster at the cell-cell 
interface, in turn, eliciting a diverse plethora of functional outcomes.  
1.2.2 Eph receptor signaling 
Clustering of Eph receptors triggers autophosphorylation of tyrosine residues in the receptor 
juxtamembrane region, kinase domain and sterile alpha-motif domain6. The phosphotyrosines 
serve as docking sites for multiple SH2-domain adaptor proteins, which may be phosphorylated 
by the kinase domain40. Depending on the cell type, context and type of ephrin/Eph involved, 
these adaptors include the non-catalytic region of tyrosine kinase (NCK), chicken tumor virus 
number 10 regulator of kinase (CRK), phosphoinositide 3-kinase (PI3K) and Src family 
kinases which regulate the activity of many downstream signaling pathways that control cell 
adhesion and cytoskeleton organization6. The major pathways are the Ras homolog (Rho) 
family of guanine triphosphate (GTP)ases and Ras-mitogen-activated protein 
kinases/extracellular signal-regulated kinases (Ras-MAPK/ERK) pathways40. For instance, 
EphA2 activation suppressed MAPK signaling in endothelial and epithelial cells by growth 
factor receptor signaling such as epidermal growth factor (EGF), preventing cell proliferation41. 
In addition, EphB2-induced downregulation of GTP-bound Ras led to subsequent inhibition of 
Ras-MAPK pathway in neuronal cells, inducing neurite retraction42.  
1.2.3 EphA2 dysregulation in cancer 
Among all the Eph receptors, EphA2 has the strongest association with cancer progression due 
to its aberrantly high expression in multiple cancer types5,43. These include cancer cell lines 
and solid tumors like breast, ovarian, melanoma, pancreas and glioblastoma associated with 
high metastatic potential, poor prognosis and patient survival43. Early in vitro work found that 
EphA2 overexpression is sufficient to transform non-malignant human breast epithelial cells 
to a malignant phenotype of high metastasis potential44. Moreover, EphA2-deficient tumors 
from breast cancer mouse models have reduced cell invasion and metastasis45. Paradoxically, 
EphA2 signaling in cancer not only has oncogenic but also tumor suppressive effects, possibly 
due to ligand-independent and ligand-dependent mechanisms5,15. Ligand-mediated activation 
of EphA2 inhibits integrin, Ras-MAPK and Rho GTPase activation, consequently suppressing 
cell adhesion, migration and proliferation21,41,46. Furthermore, the EphA2 gene was found to be 
transcriptionally regulated by the p53 family of tumor suppressors and induced apoptosis when 
overexpressed47. Emerging evidence has shown that EphA2 overexpression is often 
accompanied with low expression of ephrin-A1 (cognate ligand of EphA2) in breast cancer 
cells and glioblastoma multiforme (GBM)24,48,49. This inverse expression pattern is suggested 
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to be mediated through an active Ras-MAPK pathway that is often dysregulated in cancer50. 
Ephrin activation of EphA2 can induce suppression of the MAPK pathway by a negative 
feedback inhibition of Ras activity, downregulating EphA2 protein expression50. However, this  
negative feedback regulation was not seen in MDA-MB-231 breast cancer cells50, which have 
a constitutively active MAPK due to KRAS and BRAF gene mutations51. The tumor suppressive 
and oncogenic functions of EphA2 may also be explained by its signaling crosstalk with the 
PI3K-AKT pathway. Phosphorylation by AKT of a serine residue (S897) in EphA2 without 
ligand binding resulted in increased migration and invasion of glioma cells and stem cells, an 
effect which was reversed by ephrin-A1-EphA2 activation15,52. However, the S897 
phosphorylation can also be induced by other kinases like protein kinase A and p90 ribosomal 
S6 kinase53,54, further highlighting complex interplay of EphA2 with other signaling networks. 
Therefore, modulating the balance between EphA2 ligand-dependent and ligand-independent 
pathways may be useful to enhance tumor suppression or downregulate tumor-promoting 
signals for cancer therapy.  
1.3 T-CELL SIGNALING 
T cells are the crucial players of the body’s adaptive immune system, involved in the cell-
mediated immune response against a chronic infection/inflammation. T cells use their cell 
surface receptors, the T-cell receptor (TCR), to recognize self-derived or foreign peptide 
fragments that are bound to cell surface molecules called the major histocompatibility complex 
(MHC) expressed on their target cells. The latter can be either infected nucleated cells or 
professional antigen-presenting cells (APCs) which includes B cells, macrophages and 
dendritic cells. The TCR complex consists of the TCR antigen recognition α and β or γ and δ 
heterodimer chains in a non-covalent assembly with six cluster of differentiation 3 (CD3) 
adaptor proteins; CD3ε–CD3δ, CD3ε–CD3γ and CD3ζ–CD3ζ55,56. The TCR heterodimer has 
no intrinsic catalytic activity and relies on the CD3 cytoplasmic domains containing 
immunoreceptor tyrosine activation motifs (ITAMs) for signal transduction57. Briefly, 
recognition and binding of peptide-MHC (pMHC) by the TCR heterodimer chains lead to 
ITAM phosphorylation by lymphocyte-specific protein tyrosine kinase (LCK) and recruitment 
and activation of zeta-chain-associated protein kinase 70 (ZAP-70)58,59. Activated ZAP-70 
phosphorylates the scaffold protein linker of activated T cells (LAT) which recruits multiple 
signaling effectors that trigger activation of downstream pathways such as calcium flux and 
nuclear factor-κB (NF-κB) signaling. Calcium signaling leads to nuclear translocation and 
activation of the nuclear factor of activated T cells (NFAT). In addition to the TCR-pMHC 
interaction, engagement of T cell costimulatory receptors such as CD28 is required to elicit a 
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functional immune response. By binding to CD80/86 on APCs, CD28 costimulation activates 
PI3K/AKT and MAPK pathways which leads to the formation of the activator protein 1 (AP1) 
complex in the nucleus60. The combined activities of NFAT, AP1 and NF-κB transcription 
factors activates gene transcription such as interleukin-2 (IL-2).  
1.3.1 T-cell immunological synapse 
The area of contact between a T cell and an APC was first described as the immunological 
synapse61,62, defined as a bull’s eye-like structure of distinct protein patterns63,64. These patterns 
were described as supramolecular activation clusters (SMACs) which are organized as a TCR-
rich central core (cSMAC) surrounded by a peripheral SMAC (pSMAC) of lymphocyte 
function-associated antigen 1 (LFA-1) integrins and talin cytoskeletal proteins and a distal 
SMAC (dSMAC) of actin and CD45 tyrosine phosphatases63,65 (Figure 2). It is important to 
note that this particular synaptic structure is not universal to all interfaces between T cells and 
their target cells. The synaptic architecture varies depending on the type of T cell and APC as 
well as the overall cellular context. For example, multiple TCR-rich cSMACs have been 
reported in T cell contacts with dendritic cells66,67. Despite this, the prototypical bull’s eye 
pattern immune synapse has provided a spatial context for our understanding of T cell receptor 
signaling. 
Figure 2. A simplistic illustration of the bull’s eye pattern of the immunological synapse. 
Figure adapted from Yu et al68. 
1.3.2 TCR organization and signaling in the immunological synapse  
The use of supported lipid bilayers as an in vitro reconstitution model has been instrumental in 
characterizing the underlying processes of the immunological synapse. This approach which 
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was pioneered by Dustin and colleagues, allows visualization of T cell interactions with 
proteins such as the peptide-MHC (pMHC) and LFA-1 binding intercellular adhesion molecule 
1 (ICAM-1) attached on a planar lipid bilayer surface64,69. As these proteins linked to the lipids 
in the bilayer are highly mobile, they allow for movement of cell surface receptors following 
ligand binding. Total internal reflection fluorescence microscopy (TIRFM) is widely used to 
interrogate the molecules at the cell-bilayer interface. Using this imaging method, formation of 
TCR-pMHC microclusters was observed within 5 seconds of cell-bilayer contact70. It was 
estimated that each microcluster contains 40 – 150 TCR molecules in a 0.35 – 0.5 µm2 area70,71.  
Most of these early TCR microclusters are colocalized with other TCR signaling proteins such 
as TCR co-stimulatory protein CD28, LCK, ZAP-70, LAT and adaptor protein SH2 domain-
containing leukocyte protein of 76 kDa (SLP-76)70–72. Activated TCR signaling is indicated by 
phosphorylated ZAP-70 and tyrosine phosphorylation in most of the TCR microclusters and 
increased intracellular calcium70,71. As the cell spreads on the bilayer, newly generated TCR 
microclusters in the periphery are strongly associated with these activated kinases70. 
Concurrently, the T cell integrin LFA-1 bound to ICAM-1 on the bilayer are organized in 
microclusters spatially distinct from the TCR microclusters73. After 5 minutes of contact, most 
TCR and LFA-1 microclusters are centripetally transported by filamentous actin to form the 
cSMAC and pSMAC respectively70,71,73,74. TCR signaling is sustained by the continuous 
generation of TCR microclusters in the cell periphery associated with ZAP-70 and SLP-76 and 
their dissociation in migrating TCR microclusters to the synapse center70. In addition, CD28 
proteins are segregated from these TCR microclusters and are translocated to a separate domain 
proximal to the TCR-rich cSMAC72. This led to a notion that TCR signaling is activated and 
maintained by the TCR microclusters and that the cSMAC is associated with TCR signal 
downregulation by TCR internalization and ubiquitin-mediated degradation74–76. This was 
supported by experiments which showed that peripheral TCR microclusters remain 
phosphorylated when constrained by chromium patterns on a supported lipid bilayer, while 
TCR microclusters in the center are unphosphorylated77. Furthermore, it has been shown that 
TCR-enriched microvesicles are formed in the cSMAC and released extracellularly to activate 
B cells78. This is in agreement with prior reports showing termination of TCR signaling in the 
cSMAC through the segregation of TCR microclusters into vesicular bodies70,74. However, the 
cSMAC can become the site of sustained TCR signaling following stimulation by weak pMHC 
agonists79. Based on this evidence, the spatial organization of TCRs and its signaling molecules 
not only regulates downstream signaling but is also highly dynamic and adaptable to the 
signaling context.  
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With the advent of super-resolution microscopy, further insights into the nanoscale 
organization of TCR and its signaling partners have been discovered. Using photoactivatable 
localization microscopy (PALM), TCR and LAT were found on membrane sheets of quiescent 
T cells as spatially distinct nanoclusters that concatenated upon TCR activation80. Combination 
of PALM and direct stochastic optical reconstruction microscopy (dSTORM) showed 
increased molecular density of TCR-CD3z nanoclusters and colocalization with 
phosphorylated ZAP-70 and LAT upon TCR stimulation81. Furthermore, TCR-CD3z 
clustering was demonstrated to be independent of CD3z phosphorylation as CD3z ITAM 
mutants retained clustering ability when stimulated81. In situ evidence of preclustered TCRs on 
naïve T cells and microcluster formation after T-cell activation in mouse lymph node tissues 
was also reported using dSTORM and light sheet microscopy82. However, others have argued 
that TCRs do not reside in pre-assembled nanoclusters but instead exist as monomers that are 
randomly distributed on non-activated T cells83,84. While it is unclear whether TCRs are 
organized in nanoclusters before engaging with pMHCs, collective evidence indicates that the 
spatial reorganization of pMHC-engaged TCRs into clusters is important for signal activation 
and propagation70,74,77. In addition, it has been shown that agonistic antibodies (anti-CD3 
antibodies) or multivalent pMHC assemblies are needed to induce TCR clustering and in vitro 
T cell activation85–87. Soluble pMHC monomers bind but do not elicit TCR activation unless 
they are attached to a surface88,89 while soluble pMHC dimers are able to activate T cells90,91. 
1.3.3 PD-1 immune checkpoint 
T-cell signaling involves the TCR-pMHC ligation coupled with multiple receptor-ligand 
interactions within the immunological synapse. These interactions provide either positive 
costimulatory or negative coinhibitory signals that regulate T-cell signaling. One of the 
negative regulators is the Programmed Death 1 (PD-1) receptor and its ligands PD-L1 (B7-H1) 
or PD-L2 (B7-DC)92–95. PD-1 acts as an “immune checkpoint” to regulate effector T-cell 
responses and maintain peripheral immune tolerance96. The role of PD-1 in peripheral tolerance 
was first discovered when Pdcd1 (which encodes for PD-1) gene knockout mice developed 
autoimmune diseases97,98. PD-1 is expressed in activated T cells upon acute antigen stimulation 
and then downregulated after antigenic clearance99,100. In contrast, PD-1 expression is sustained 
at high levels in T cells exposed to prolonged antigenic stimulation in chronic inflammation100. 
These T cells progressively become dysfunctional or “exhausted”, exhibiting loss of effector 
functions including cytokine and chemokine production as well as upregulation of other co-
inhibitory markers101,102. This is observed in tumor-infiltrating T cells in cancers including 
ovarian103, breast,104 and melanoma105. Moreover PD-L1 expression is induced in the pro-
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inflammatory tumor microenvironment96. Thus, blocking PD-1 signaling would reinstate the 
T cell anti-tumor response106,107. In recent years, this approach has achieved tremendous 
clinical success as one of the immune checkpoint blockades in cancer immunotherapy, 
culminating in the Nobel Prize in Physiology or Medicine in 2018108. 
1.3.4 PD-1 in the immunological synapse 
PD-1 was first reported to localize in the immunological synapse of T cells and dendritic 
cells109. Later studies using reconstituted supported lipid bilayers observed formation of PD-1 
microclusters upon PD-L1 binding110–112. At initial cell-bilayer contact, the PD-1 microclusters 
are mostly colocalized with the TCR microclusters but strongly colocalized with CD28 
microclusters110,111. As the cSMAC is formed, PD-1 molecules are organized together with 
CD28 molecules around the cSMAC, segregated from the TCR-rich core110,111. Upon PD-L1 
binding, LCK-mediated phosphorylation of the PD-1 cytoplasmic domain occurs at the 
immunoreceptor tyrosine-based switch motif (ITSM) and immunoreceptor tyrosine-based 
inhibitory motif (ITIM). This triggers the recruitment of Src homology 2 domain–containing 
tyrosine phosphatase 2 (SHP2)110,111,113(Figure 3). PD-1 negative suppression of T-cell 
signaling was observed by the recruitment of SHP2 in the early PD-1 microclusters and 
dephosphorylation of TCR-CD3z and CD28 molecules110,111. Recently, it has been shown that 
SHP2 induced PD-1 intracellular dimerization by binding to phosphotyrosines of the ITSMs 
of two PD-1 proteins114. While SHP2 is considered the primary mediator for PD-1 inhibitory 
effects, it appears that PD-1 can modulate T-cell signaling through SHP2-independent 
mechanisms115–117. The underlying mechanisms of how PD-1 signaling negatively regulates T-
cell activation have been actively debated. Some studies have reported that PD-1 suppresses 
signaling through the TCR-CD3 complex110,113,118, whereas others have argued that the CD28 
pathway is preferentially targeted by PD-1111,116. In addition, CD28 costimulation is crucial for 
restoring T-cell proliferation after PD-1 blockade during chronic infections119. Interestingly, it 
was reported in the absence of CD28 costimulation, liganded PD-1 resided with another T-cell 
costimulatory receptor CD2 in the edge of the immunological synapse and reduced CD2 
costimulation effect on TCR signaling120. This suggests an alternative mechanism of PD-1 
negative regulation on T-cell signaling. While most studies focus on the PD-L1/PD-1 signaling 
in trans, a recent study showed that cis interactions of PD-1 and PD-L1 can occur in APCs to 
prevent binding of PD-L1 to PD-1 on T cells112. These evidences highlight the complexities of 
PD-1 signaling, making it difficult to draw the exact mechanisms of action by which PD-1 
inhibits T-cell activation.  
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Based on structural and biophysical studies, PD-1 is expressed as a monomer on the cell surface 
and forms a 1:1 complex with PD-L1121,122. Thus, PD-L1 dimerization induced by small 
molecule inhibitors prevent the binding of PD-L1 to PD-1 and this enabled in vitro T cell 
reactivation123,124.  However, a recent report identified a secreted PD-L1 splice variant from 
tumor cells that was able to form homodimers, which inhibited in vitro T-cell functions more 
strongly than soluble PD-L1 monomers125. Therefore, it is unclear whether the spatial 
proximity of PD-L1 ligands contribute to PD-1 inhibitory effects of T-cell signaling.  
 
Figure 3. Brief schematic of the general notion of PD-1 signaling mechanism. T cell activation 
is initiated by pMHC-TCR binding and CD28 co-stimulation. PD-1 becomes expressed and 
binds to PD-L1/L2 on APCs or tumour cells. LCK-mediated phosphorylation at ITIM and 
ITSM of PD-1 leads to recruitment of phosphatases, including SHP-2. SHP2 mediates 
dephosphorylation of CD3ζ, ZAP-70 and CD28, therefore counters the activation of T cell 
signaling. Inhibitory signals (red blocked arrows). 
1.4 DNA ORIGAMI  
DNA origami is a technique that uses DNA as a structural material to drive self-assembly of 
2D and 3D structures with nanoscale precision and programmability. First demonstrated by 
 
 11 
Paul Rothemund in 2006, the technique involves mixing of a long circular single-stranded 
DNA (“scaffold”), usually obtained from the M13 bacteriophage, with many short single-
stranded oligonucleotides (“staples”)126. The staples are designed to bind complementarily to 
specific regions of the scaffold. Thus, this folds the scaffold into a predefined structure 
analogous to the art of paper folding (hence the name “DNA origami”) (Figure 4).   
Figure 4. Principle of the DNA origami technique.  
Since Rothemund’s work on 2D sheets of monolayered DNA helices, the technique has rapidly 
developed to build 3D objects of any arbitrary shape including boxes with controllable lids127, 
monolithic constructs128 and curved structures129130. The early generation 3D structures were 
produced by closely packing bundles of DNA double-helices in honeycomb or square 
lattices128,129,131,132. DNA origami design with these geometries can be performed using the 
computational software caDNAno and model prediction tool CanDo131,133. However, the 
approach of densely packing of DNA helices uses more scaffold material and thus limits the 
dimensions of structures that can be constructed. More importantly, high cationic strength 
conditions are required to neutralize the electrostatic repulsion between the closely packed 
helices to prevent structure disintegration. To circumvent these caveats, new strategies based 
on wireframe designs have been developed to construct complex 2D and 3D polyhedral 
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structures134–138. The sparse wireframe geometries maximize the scaffold length, giving rise to 
larger surface areas. Furthermore, the structures can be folded and remain stable in 
physiological salt conditions134, which makes them ideal for biomedical applications.  
1.4.1 DNA origami as a tool for creating nanoscale patterns  
The power of DNA origami is its spatial addressability which stems from the well-defined 
double helical geometry of DNA and the unique sequence of every staple and their specific 
positions in the final construct. The B-form DNA is commonly found in living cells and has a 
right-handed helix of a diameter of ~2.4 nm and a complete helical turn of ~3.4 nm for every 
10.5 base pairs (bp)139. In honeycomb-based DNA origami constructs, crossovers from either 
the scaffold or staple strand connect neighboring DNA double helices. This creates sites of 
regular spacing of ~7 nm (21 bp) along the helical direction for functionalization131. By 
modifying individual staple strands, this enables positioning of diverse molecules including 
RNA140, proteins141–143, nanoparticles144 and quantum dots145, with nanometer precision. Hence 
the DNA origami method has been used extensively to produce nanoscale patterns in various 
applications. These include nanofabricated scaffolds for synthesis and assembly of 
nanoparticles146,147, studying of biomolecular interactions and enzymatic cascades142,148–150 as 
well as creation of nano-ruler standards for quantitative super-resolution imaging151–153. In 
addition, DNA origami nanostructures have been used to interrogate the spatial organization 
of membrane proteins in the contexts of ephrin-Eph signaling and viral antigenic-mediated B-
cell receptor triggering39,154. 
Notably, DNA origami nanostructures as nanodevices for delivery of therapeutic molecules 
have been of major interest. Owing to its high structural programmability, DNA origami has 
enabled customized configurations for cellular delivery and controlled release of drug 
molecules155,156. In vitro and in vivo cellular targeting with various biomolecules including 
doxorubicin156,157, immunostimulatory DNA158, antibodies155 and small interfering RNAs159 
loaded onto DNA origami nanostructures have been reported. Recent work has utilized DNA 
origami nanostructures loaded with tumor neoantigens as a cancer vaccine to trigger T-cell 
anti-tumor response in mouse cancer models160. Overall, the DNA origami technique have 
contributed to diverse applications from nanofabrication to in vitro and in vivo drug delivery 







2 RESEARCH AIMS 
The overall aim of the work in this thesis is to investigate the role of spatial organization of 
ligands on membrane receptor activation and downstream signaling responses by using DNA 
origami as a nanoscale patterning tool. This work addresses the spatial organization of ligands 
as an important biophysical factor in modulating receptor-mediated responses in two cellular 
signaling contexts. The following papers specifically aimed: 
PAPER I – To investigate the role of the nanoscale spatial organization of ephrin-A5 ligands 
on EphA2 receptor activation and downstream transcriptional responses using ephrin-A5-
patterned honeycomb DNA origami nanostructures. 
  
PAPER II – To investigate the role of nanoscale spatial organization of PD-L1 on T-cell 
signaling and PD-1 distribution on the membrane using wireframe DNA origami flat sheets 







3 MATERIALS AND METHODS 
3.1 DNA ORIGAMI DESIGN AND FUNCTIONALIZATION 
 
The work in this thesis employed two previously published designs of DNA origami 
nanostructures for nanoscale protein patterning39,137. In paper I, the DNA origami design 
described as a DNA nanocaliper, was an 18-double helix bundle arranged in a honeycomb 
lattice (Figure 5). In paper II, the DNA origami wireframe flat sheet design was used 
(Figure 6a). The single-stranded scaffolds for the honeycomb and wireframe designs are p7560 
and p8064 respectively which are isolated from M13mp18 phage derivatives. In a “one-pot” 
reaction, the scaffold strands are mixed with a large molar excess of staples in a Tris-acetate-
EDTA (TAE) buffer (pH 8) with 13 mM magnesium chloride (MgCl2) for the DNA 
nanocaliper folding. The 1× phosphate-buffered saline (PBS) (pH 7.4) was used as a buffer for 
folding the DNA flat sheets. The DNA origami nanostructures were assembled through an 
annealing process on a thermal cycler that involves an initial heat denaturation step and 
subsequent gradual cooling over a 14-hour period. After folding, the assembled DNA origami 
nanostructures are separated from the excess staples by several rounds of diafiltration using 
Amicon® Ultra centrifugal filter columns. 
Figure 5. Stylized rendering of the DNA nanocaliper in three views (a) Perspective. (b) Front. 
(c) Side. The scaffold and staples are depicted as light grey and pink strands respectively.  
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To create sites for protein binding to the DNA origami, protruding staples containing a 
5’overhang sequence are incorporated in the staple mix during the folding process (Figure 6b). 
Proteins that are conjugated to oligonucleotides would hybridize to the overhangs at these 
specific sites via complementary base pairing.  
Figure 6. (a) Stylized rendering of the DNA wireframe origami flat sheet. The single-stranded 
scaffold strand (light grey) is folded by staple strands (blue) based on a triangulated mesh. (b) 
Illustration of protein binding to the DNA origami flat sheet. Two staples in the origami (left, 
orange arrows) are replaced with staples with a 19 or 21 bp extension at the 5’ ends. This would 
allow hybridization by complementary base pairing with oligonucleotides that are conjugated 
to proteins (right).  
Using this principle, protein patterns of different spatial distances and configurations can be 
assembled on the DNA origami. In paper I, the DNA nanocaliper was used to present four 
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different ephrin-A5 patterns. In paper II, T-cell activating DNA flat sheets were designed to 
present either the anti-CD3 antibody alone or a pair of anti-CD3 and anti-CD28 antibodies. The 
panel of PD-L1 flat sheets was designed with four different PD-L1 patterns. In addition, biotin-
modified staples were introduced during the folding of the DNA flat sheets. This allows for 
immobilization of the protein-flat sheets on a streptavidin-biotin surface in subsequent cell 
stimulation experiments.  
3.2 PRODUCTION OF PROTEIN-OLIGONUCLEOTIDE CONJUGATES 
The oligonucleotides used for the protein conjugations are modified with an azide moiety at 
the 3’ end. Conjugation of the 6-histidine (His6)-tagged proteins (recombinant human ephrin-
A5-Fc chimera and PD-L1) was adapted from a previously described histidine tag-specific 
polyethylene glycol (PEG) conjugation method161. The proteins are functionalized by 
crosslinking bis-sulfone-PEG4-dibenzocyclooctyne (DBCO) molecules to the imidazole side 
chains of the histidine tags (Figure 7).  
Figure 7. Schematic workflow of the histidine-tag directed conjugation of the ephrin-A5-Fc 
dimer and PD-L1 protein. The bis-sulfone-PEG4-DBCO reagent is used for the incorporation 
of the DBCO moiety onto the proteins via their His6-tags. The protein-oligonucleotide 
conjugates are formed via a copper-free click reaction of the DBCO group on the proteins and 
the azide-modified oligonucleotides. 
As for the antibodies anti-CD3 and anti-CD28, they were functionalized by DBCO-N-
hydroxysuccinimide (NHS) esters which targets primary amine groups, for example the side 
chains of lysine residues. The DBCO groups in the proteins then react to the azides in the 
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oligonucleotides via a copper-free click chemistry reaction. The resulting protein-
oligonucleotide conjugates are purified using ultrafiltration to remove unconjugated 
oligonucleotides. The quality of protein-oligo conjugates was then assessed by 4-20% native 
polyacrylamide gel electrophoresis (PAGE) and silver staining after hybridization of 
fluorescently-labeled complementary oligonucleotides as well as reducing sodium dodecyl 
sulfate (SDS)-PAGE. 
3.3 PRODUCTION AND CHARACTERIZATION OF PROTEIN-
FUNCTIONALIZED DNA ORIGAMI 
The protein-oligonucleotide conjugates are mixed with the assembled DNA origami at a 5-
fold molar excess per binding site. Hybridization between the conjugates and the DNA origami 
was performed at 37°C for 1 hour, followed by rapid cooling to 22°C and then incubated for 
14 hours. After incubation, the protein-DNA origami nanostructures are stored at 4°C.  Excess 
protein-oligonucleotides are separated from the protein-DNA origami by gel filtration using 
Sepharose 6B resin packed columns (Figure 8). The quality and protein functionalization of 
the DNA origami were assessed by agarose gel electrophoresis. Despite their large size, the 
DNA nanocalipers migrate faster through the gel than the single-stranded scaffold due to the 
former’s compact conformation. 
 Figure 8. General overview of the production workflow of the protein-DNA origami 
nanostructures (ephrin-A5 DNA nanocaliper as an example). Folding of the DNA nanocaliper 
requires the presence of magnesium cations (Mg2+). Diafiltration is performed to enrich the 
DNA nanocalipers and remove the unincorporated staples. The purified DNA nanocalipers are 
then mixed with the ephrin-A5-Fc-oligo conjugates for the hybridization reaction. The latter 
undergoes Sepharose 6B gel filtration to remove the non-hybridized conjugates and then 
assessed by agarose gel electrophoresis.  
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The gel migration distances were also used to determine whether the nanocalipers contain the 
ephrin-A5-Fc dimers. On the other hand, wireframe flat sheets migrate slower than the scaffold 
strand, possibly due to its open conformation. The proteins on the flat sheets were detected by 
in-gel fluorescence from fluorescently-labeled antibody binding. Transmission electron 
microscopy (TEM) and atomic force microscopy (AFM) were used for imaging the DNA 
nanocalipers and the flat sheets respectively and to confirm the assembly of proteins according 
to design.  
3.4 CELLULAR READOUT EXPERIMENTS 
3.4.1 Paper I: In situ proximity ligation assay (PLA) 
Human breast cancer cell line MDA-MB-231 and human patient-derived U3013 glioblastoma 
cells were seeded on glass coverslips 24 hours before treatment with ephrin-A5 nanocalipers. 
MDA-MB-231 cells were starved in reduced amounts of serum for 24 hours to decrease 
baseline phosphorylation levels. The cells were treated with the nanocalipers presenting ephrin-
A5-Fc dimers of different distances in a PBS solution supplemented with 13 mM MgCl2 and 
incubated for 15 and 30 minutes.  
To detect EphA2 receptor phosphorylation, the cells were fixed and processed using the 
Duolink® PLA kit (Sigma-Aldrich) according to manufacturer’s guidelines. This method is 
based on the principle of close proximity binding of anti-phosphotyrosine antibodies and 
antibodies that target the intracellular domains of EphA2 (Figure 9). This allows for a 




Figure 9. Schematic outline of the PLA to detect EphA2 tyrosine phosphorylation. First, two 
antibodies recognize the phosphorylated tyrosine residues (pY) and the cytoplasmic region of 
EphA2. These antibodies are targets for binding of secondary antibodies conjugated with 
oligonucleotides (PLA probes). If the PLA probes bind in close proximity (< 40 nm), this would 
guide two connector oligonucleotides with 5’ phosphate ends (blue dots) to form a circular 
DNA structure by enzymatic DNA ligation. Rolling circle amplification (RCA) is initiated by 
the phi-29 DNA polymerase which uses an oligonucleotide of one PLA probe as a primer 
(dotted arrow). The oligonucleotide of the other probe contains a 2’O-methyl RNA 
modification at the 3’end, which blocks the polymerase from using it as a primer for the RCA. 
Using the circularized single-stranded DNA as a template, the polymerase generates a 
concatemer of multiple repeats that are complementary to the DNA circle template. Finally, 
the DNA concatemer is detected by complementary fluorescently-labeled oligonucleotides. 
Figure is adapted from the paper that showed the first demonstration of the in situ PLA 
technique162.  
3.4.2 Paper II: Luciferase reporter assay 
To measure T cell activation in response to antibody and PD-L1 DNA origami flat sheets, a 
commercially available Jurkat T cell line constitutively expressing PD-1 and a nuclear factor 
of activated T cells (NFAT) response element-firefly luciferase gene reporter (BPS Bioscience) 
was used. The cells were stimulated by antibody and PD-L1 flat sheets coated on streptavidin-
biotinylated bovine serum albumin (BSA) surface for 3 hours before cell lysis and luciferase 
activity measurements. Anti-CD3 and CD28 antibody-induced T-cell activation triggers 
expression of the luciferase protein via activation of NFAT and binding to the response 
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elements. The luciferase activity is quantified by the bioluminescence generated from the 
luciferase-driven catalysis of the luciferin substrate.  
3.4.3 Paper II: Generation of PD-1-expressing T-cell model for super 
resolution microscopy 
To investigate the PD-1 distributions on the cell membrane, Jurkat E6-1 cells were retrovirally 
transduced to express PD-1 fused with an intracellular SNAP-tag protein. The SNAP-tag is a 
20 kDa mutant DNA repair enzyme O6-alkylguanine-DNA alkyltransferase, which allows 
covalent labeling of benzylguanine-modified fluorophores to the protein. The SNAP-tag offers 
specific protein-labeling of organic fluorescent dyes which have higher photon-output and 
photostability than fluorescent proteins163. Moreover, the large size of fluorescent protein tags 
and their tendency to oligomerize reduce the precision of target protein localization. For this 
purpose, an 880 bp cDNA sequence encoding the human PD-1 (R&D Systems) was subcloned 
into the pSNAPf vector (New England Biolabs), as a fusion to the N-terminus of the SNAP-
tag. Restriction enzymatic digestion was performed to obtain the PD-1-SNAP construct and 
then cloned into a murine stem cell retrovirus plasmid (pMSCV) containing the neomycin 
resistance gene (kindly given by Dr. Stephen L. Lessnick from Nationwide Children’s 
Hospital). The retrovirus construct containing the PD-1-SNAP insert was sent to the Vector 
Facility in Lund University for retroviral vector production. Jurkat cells were retrovirally 
transduced at a multiplicity of infection (MOI) of 20 and then selected for G418 (neomycin 
analogue) antibiotic resistance. Single cells were isolated by the limiting dilution method to 
obtain a monoclonal cell population expressing the PD-1-SNAP-tag fusion protein. Surface 
expression of PD-1 was estimated by flow cytometry based on fluorescence quantitation with 
phycoerythrin-labeled anti-PD-1 antibodies and Quantibrite™ beads (BD Biosciences). In 
addition, PD-1 and SNAP expression were assessed by Western blot. The cells were further 
characterized for IL-2 expression by enzyme-linked immunosorbent assay (ELISA) when 




4 RESULTS & DISCUSSION 
4.1 PAPER I  
4.1.1 Ephrin-A5 DNA nanocaliper production and characterization 
We used the designs of the ephrin-A5 functionalized DNA nanocaliper as previously 
published39 to study the effects of nanoscale spatial organization of ephrin-A5 on EphA2 
receptor phosphorylation and transcriptional response. We adapted a polyhistidine tag-specific 
labeling approach for covalent conjugation of DNA to His6-tagged ephrin-A5-Fc dimers. This 
method gives more control in the protein modification and minimizes interference in protein 
functionality from random labeling by primary amine or sulfhydryl group-based 
bioconjugation strategies. Based on the native polyacrylamide gel fluorescence and silver stain, 
two ephrin-A5-Fc-oligonucleotide products were detected with differing fluorescent intensities 
that suggest one or two oligonucleotides were coupled to the ephrin-A5-Fc dimer. More 
importantly, the in-gel fluorescence showed that the unincorporated azide-oligonucleotides 
were efficiently removed from the ephrin-A5-oligonucleotide conjugate reaction after 
diafiltration. The ephrin-A5-oligonucleotide conjugates were then incorporated to the DNA 
nanocalipers via hybridization to the protruding staples at different positions, producing a panel 
of nanocalipers that present one ephrin-A5 dimer (NC-0) or two dimers separated by 14.3 nm 
(NC-14), 42.9 nm (NC-40) and 101.1 nm (NC-100).  
We verified the DNA nanocalipers functionalized with the ephrin-A5-oligonucleotide 
conjugates by agarose gel electrophoresis and TEM imaging (Figure 10). In the agarose gels, 
the ephrin-A5 DNA nanocalipers migrated at shorter distances than the non-functionalized 
DNA nanocaliper (NC-empty). In addition, DNA nanocalipers with two ephrin-A5 dimers 
(NC-14, NC-40 and NC-100) had shorter gel migration distances than the nanocalipers with 
one ephrin-A5 dimer (NC-0). We also confirmed binding of recombinant EphA2 proteins to 




Figure 10. Respective TEM and agarose gel images of the DNA nanocalipers presenting 
ephrin-A5-Fc dimers at different positions.  
4.1.2 EphA2 receptor activation is spatially regulated by ephrin-A5 DNA 
nanocalipers  
Next, we investigated the effect of EphA2 receptor activation in MDA-MB-231 breast cancer 
cells and U3013 glioblastoma cells in response to stimulations by the different ephrin-A5 
nanocalipers at two stimulation times. Using the PLA method, we observed increased EphA2 
phosphorylation in MDA-MB-231 and U3013 cells after 15 minutes of stimulation by the 
ephrin-A5 DNA nanocalipers. At this timepoint, we observed that NC-40 and NC-100 induced 
the highest level of EphA2 phosphorylation in MDA-MB-231 and U3013 cells, respectively. 
In MDA-MB-231 cells, levels of EphA2 phosphorylation induced by NC-40 also significantly 
differed from those by NC-0 and NC-100. In U3013 cells, NC-100 induced differential EphA2 
phosphorylation levels compared to NC-0, NC-14 and NC-40. After 30 minutes of stimulation, 
both cell types showed variable EphA2 phosphorylation levels, with only NC-40 inducing 
significant phosphorylation. Overall, these results suggest that EphA2 phosphorylation is 
regulated by ephrin-A5 spatial distribution at a short stimulation time (15 min).  
NC-empty NC-0 NC-14 NC-40 NC-100
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4.1.3 U3013 cells showed more EphA2-associated transcriptional responses 
to “classical” EphA2 stimulation than MDA-MB-231 cells  
The standard approach for in vitro Eph receptor clustering and activation involves pre-
clustering of recombinant ephrin-Fc fusions by anti-Fc antibodies in solution before cell 
stimulation. This method yields a heterogeneous mixture of higher-order ephrin oligomers and 
therefore does not allow for control of ligand cluster sizes. We sought to understand the 
transcriptional profiles of MDA-MB-231 and U3013 cells after EphA2 activation with this 
method. For this purpose, we performed RNA-sequencing with low cell numbers (~400 cell 
equivalents) based on an adaptation of the Smart-seq2 protocol164. We observed that U3013 
cells showed more EphA2-associated pathways that are significantly enriched compared to 
those found in MDA-MB-231 cells. This indicates that the former is more transcriptionally 
responsive to EphA2 activation. 
4.1.4 Divergence in the EphA2-associated transcriptional response to 
increasing ephrin-A5 spatial distance 
As the U3013 cells are more responsive to EphA2 activation at the transcriptomic level, we 
further analyzed their transcriptome after cell stimulation with the different ephrin-A5 
nanocalipers. Increasing ephrin-A5 dimer distances up to ~100 nm on the DNA nanocaliper 
(NC-100) increased the number of differentially expressed (DE) genes. This is accompanied 
by a decreasing percentage of DE genes overlapping with one or more nanocaliper data sets   
as the spatial distance between ephrin-A5 dimers increases. This spatially-induced divergence 
in EphA2 transcriptional response is supported by correlation analyses, which showed that the 
NC-40 and NC-100 induced EphA2 transcriptional responses that are distinct from those by 
NC-0 and NC-14 stimulation. Additionally, pathway enrichment analysis showed distinct 
significantly enriched pathways induced by the different ephrin-A5 nanocaliper conditions. 
Intriguingly, while NC-40 and NC-100 differed in their significantly enriched pathways, some 
of those are subsets of pathways triggered by antibody-clustered ephrin-A5 stimulation 
(Figure 11). Together, these results indicate that the spatial distance of ephrin-A5 dimers at the 




Figure 11. A Euler diagram illustrating the induced significantly enriched pathways between 
antibody-clustered ephrin-A5 and ephrin-A5 DNA nanocaliper stimulations.   
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4.2 PAPER II 
4.2.1 Production of antibody- and PD-L1-patterned DNA wireframe origami 
flat sheets  
For T cell activation, DNA wireframe origami flat sheets were functionalized with a single 
anti-CD3 antibody (FS-α-CD3) or anti-CD3 and CD28 antibodies (FS-α-CD3-CD28) 
(Figure 12). A panel of PD-L1-patterned flat sheets were constructed as follows; a single 
PD-L1 protein (FS-PD-L1) and two PD-L1 proteins separated by 13.6 nm, 43.5 nm and 
202.3 nm (FS-PD-L1-13, FS-PD-L1-40 and FS-PD-L1-200).  
 Figure 12. The antibody and PD-L1 flat sheet designs and their respective AFM images.  
Using agarose gel electrophoresis, the protein-flat sheets showed no detectable difference in 
gel migration compared to flat sheets with no proteins attached (FS-empty). Hence, the 
protein-flat sheets were pre-mixed with fluorescently-labeled antibodies that recognize the 
antibody-Fc domains and PD-L1 proteins to allow for in-gel fluorescence detection. AFM 
imaging was performed to confirm the protein occupancy as designed, which was estimated to 
be about 40-65%. Additionally, surface plasmon resonance measurements validated the 
binding of PD-L1 flat sheets to PD-1 receptors.  
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4.2.2 Modulation of T-cell signaling and PD-1 clustering by PD-L1 spatial 
distances 
PD-1-expressing Jurkat T cells with a NFAT-driven luciferase reporter were stimulated with 
antibody- and PD-L1-patterned flat sheets. We observed a significant decrease in 
antibody-induced NFAT-luciferase activity only when cells were co-stimulated with 
FS-PD-L1-200. Co-stimulation with flat sheets containing a single PD-L1 or two PD-L1 
proteins spaced 13 or 40 nm apart did not result in a significant change in antibody-induced 
NFAT-luciferase activity. Furthermore, the reduction in NFAT-luciferase activity by 
FS-PD-L1-200 is dependent on the molar ratio of FS-PD-L1-200 to antibody-flat sheets, in 
which FS-PD-L1-200 at a 10-fold molar excess of the antibody-flat sheets was needed for 
significant change. Co-stimulation with FS-PD-L1-200 also led to a significant decrease in 
IL-2 gene expression in Jurkat T cells expressing PD-1 with a SNAP-tag (PD-1-SNAP).  
Analyzing the membrane distribution of PD-1 receptors in these cells by stimulated emission 
depletion (STED) imaging found an increase in the density of PD-1 clusters upon PD-L1 flat 
sheet stimulation. FS-PD-L1-200 and the antibody-flat sheet negative controls mostly triggered 
small PD-1 clusters (~50-100 nm) while FS-PD-L1-13 induced larger clusters (>100 nm). 
Together, these results show that the spatial organization of PD-L1 at the nanoscale regulates 










This thesis presents a multidisciplinary body of work integrating DNA origami technology, 
next-generation sequencing, super-resolution microscopy and molecular biology techniques to 
examine the role of nanoscale spatial organization of ligands on ligand-receptor pathways in 
the contexts of cancer biology and immunology. We used the DNA origami technique as a 
nanoscopic tool to present ligands at precise nanoscale distances that would guide the 
organization of cell membrane receptors into defined configurations. In paper I, we 
demonstrated how the spatial organization at the cell interface contributes to the ensuing events 
in the ephrin-Eph signaling. We showed that the nanoscale spatial organization of ephrin-A5 
dimers regulates early EphA2 receptor activity and downstream transcriptional responses. As 
Eph signaling is interweaved with pro-tumorigenic and tumor suppressive pathways, this 
complicates the development of effective anti-cancer agents against ephrin-Eph signaling. The 
knowledge gained from this study may provide a basis for new strategies to selectively target 
specific pathways in ephrin-Ephrin signaling for anti-cancer therapy.  
The spatial organization of T-cell signaling proteins is a key biophysical regulator of signal 
transduction in the immunological synapse. As seen in paper II, we demonstrated that the 
spatial organization of PD-L1 controls T-cell signaling and functional response of IL-2 gene 
expression (paper II). This work highlights that the spatial organization of co-inhibitory 
proteins also contributes to signal regulation in the T-cell immunological synapse. The spatial 
organization of PD-L1/PD-1 may be used as a mechanical stimulus in new cancer 







6 POINTS OF PERSPECTIVE 
To understand the mechanism behind the spatial regulation of EphA2 transcriptional 
response, it would be interesting to examine how EphA2 clusters on the membrane upon 
binding to the ephrin-A5 nanocalipers. We hypothesize that NC-40 and NC-100 induce 
two sites of EphA2 receptor dimerization spaced 40 and 100 nm apart on the cell membrane 
that might initiate recruitment of more EphA2 receptors to the sites. It might be possible 
that the two EphA2 dimers merge into a large cluster, with NC-100 resulting in larger 
receptor cluster than NC-40. On the other hand, NC-14 may have introduced a single 
receptor cluster/oligomerization site due to the proximity of the two ephrin-A5 dimers. NC-
0 with a single ephrin-A5-Fc dimer may have triggered dimerization of EphA2 receptors. 
As the starting EphA2 clustering sites are small, receptor clustering induced by NC-0 and 
NC-14 may take a longer time as compared to NC-40 and NC-100. This hypothesis may 
explain the observation of the diverging response of EphA2 signaling from the nanocaliper 
stimulations, with NC-100 inducing the largest response. Live cell imaging using super 
resolution microscopy techniques may shed light on the Eph receptor cluster formation as 
well as the kinetics in response to the different ligand nanoscale distances. The kinetics of 
the clustering can be used as a basis to elucidate the mechanisms with the transcriptional 
responses induced by the nanocalipers at different stimulation times. 
The exact molecular mechanism underlying the regulation on T-cell activation by PD-L1 
spatial distances requires further exploration. An in-depth investigation of the recruitment 
of PD-1 signaling adaptors SHP1/SHP2 in response to the PD-L1 flat sheets is essential to 
provide a better understanding of the spatial regulation induced by PD-L1. As PD-1 
microclusters have been shown to strongly associate with CD28 receptor clusters on 
supported lipid bilayers in the literature, it would be worth investigating the spatial distance 
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